Avastin
Page last modified on: May 8, 2008
Avastin (chemical name: bevacizumab) is a targeted therapy that was approved by the U.S. Food and Drug Administration (FDA) in combination with Taxol (chemical name: paclitaxel) in February 2008 to treat people with metastatic HER2-negative breast cancer who haven't yet received chemotherapy for metastatic breast cancer.
In this section you can read about:
Avastin is also approved by the FDA to treat advanced cancers of the lung, colon, and rectum.
